Glomerular filtration rate change during chronic hepatitis C treatment with Sofosbuvir/Ledipasvir in HCV/HIV Coinfected patients treated with Tenofovir and a boosted protease inhibitor: an observational prospective study.

ABSTRACT: INTRODUCTION:Concomitant use of ledipasvir and boosted protease inhibitors (PIs) may increase the risk of tenofovir (TDF) nephrotoxicity, since both these drugs increase TDF levels. Our aim was to evaluate glomerular filtration rate (eGFR) evolution during HCV treatment with sofosbuvir/ledipasvir (SOF/LDV) in HCV/HIV coinfected patients, according to their antiretroviral treatment (ARV). METHODS:Observational prospective study of HCV/HIV coinfected patients treated with SOF/LDV. eGFR evolution was evaluated during and 12 weeks after HCV treatment. Patients were categorized in three groups based on ARV regimen: non TDF, non-boosted TDF and TDF?+?boosted PI. RESULTS:We included 273 patients: 145 were receiving a non-TDF regimen, 78 a non-boosted TDF scheme and 50 were receiving TDF?+?boosted PI. We observed a statistically significant decrease in eGFR during treatment in all groups (non TDF p?=?0.03, 95%CI [0.23-3.86], non-boosted TDF p?

SUBMITTER: Soeiro CASP 

PROVIDER: S-EPMC6090809 | biostudies-literature | 2018 Aug

REPOSITORIES: biostudies-literature